MedTrace Logo

OPALINE : A Study Of Morbidity And Mortality At 2 Years

NCT02264665 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 144

Last updated 2023-11-13

Study results available
· View outcomes & findings →

Summary

A descriptive, prospective (partly retrospective), multisite, observational study conducted in France in adult patients treated for a well differentiated, unresectable or metastatic, pancreatic neuroendocrine tumor with disease progression.

Conditions

  • Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive

Interventions

DRUG

sunitinib

sunitinib 37.5mg/d orally

DRUG

everolimus

everolimus 10mg/d orally

DRUG

chemotherapies recommended in france

depends on the chemotherapy prescribed (IV)

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Keyrus Biopharma

    collaborator OTHER

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-12
Primary Completion
2019-11-18
Completion
2019-11-18

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02264665 on ClinicalTrials.gov